Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16128132 | 0.83 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL16094297 | 0.82 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL16094279 | 0.82 | P2RX7 (0.80) | P2RX7 | |
| SCHEMBL16094122 | 0.81 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL16094389 | 0.81 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL16094023 | 0.81 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL16128029 | 0.81 | P2RX7 (0.75) | P2RX7 | |
| SCHEMBL16094272 | 0.81 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL16093799 | 0.81 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL16094174 | 0.80 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-21 | — | — | US | claimed |
| US-20160016962-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | claimed |
| EP-2970304-A1 | P2X7 MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152537-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-21 | — | — | US | disclosed |
| US-20160016962-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016962-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016962-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| EP-2970304-A1 | P2X7 MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152537-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152537-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016962-A1 | P2X7 MODULATORS | P2RX5, P2RX1, P2RX7 | P2RX7 3/4885 |
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | HTR5A, P2RX5, P2RX3 | P2RX7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.